| 000 | 01429 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250518092928.0 | ||
| 264 | 0 | _c20210611 | |
| 008 | 202106s 0 0 eng d | ||
| 022 | _a2405-8025 | ||
| 024 | 7 |
_a10.1016/j.trecan.2020.01.015 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGiguère, Vincent | |
| 245 | 0 | 0 |
_aDNA-PK, Nuclear mTOR, and the Androgen Pathway in Prostate Cancer. _h[electronic resource] |
| 260 |
_bTrends in cancer _c04 2020 |
||
| 300 |
_a337-347 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAndrogens _xmetabolism |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Nucleus _xmetabolism |
| 650 | 0 | 4 |
_aChromatin _xmetabolism |
| 650 | 0 | 4 |
_aDNA-Activated Protein Kinase _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aGene Expression Regulation, Neoplastic _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aReceptors, Androgen _xmetabolism |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 |
_aTOR Serine-Threonine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aTranscription Factors _xantagonists & inhibitors |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 773 | 0 |
_tTrends in cancer _gvol. 6 _gno. 4 _gp. 337-347 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.trecan.2020.01.015 _zAvailable from publisher's website |
| 999 |
_c30777601 _d30777601 |
||